Product Description
Sitagliptin is used along with diet and exercise and sometimes with other medications to lower blood sugar levels in adults with type 2 diabetes (condition in which blood sugar is too high because the body does not produce or use insulin normally). Sitagliptin is in a class of medications called dipeptidyl peptidase-4 (DPP-4) inhibitors. It works by increasing the amounts of certain natural substances that lower blood sugar when it is high. Sitagliptin is not used to treat type 1 diabetes (condition in which the body does not produce insulin and therefore cannot control the amount of sugar in the blood). (Sourced from: https://medlineplus.gov/druginfo/meds/a606023.html)
Mechanisms of Action: DPP4 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Pancreatitis | Acidosis | Diabetic Ketoacidosis | General Diabetes | Type 2 Diabetes | Myocardial Infarction | Hyperlipidemia | Stroke | Pancreatitis | Dyslipidemia | General Diabetes | Hypercholesterolemia | Hypertriglyceridemia | Type 2 Diabetes
Known Adverse Events: Headache | Nasopharyngitis | Pharyngitis | Respiratory Tract Infections | Hypoglycemia | Abdominal Pain | Pain Unspecified | Constipation
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, China, Egypt, Germany, Mexico
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Healthy Volunteers|Obesity|Type 2 Diabetes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ACTRN12624001022550 | P1 |
Recruiting |
Obesity|Type 2 Diabetes |
2025-10-28 |
|
| SME-033-23 | P1 |
Not yet recruiting |
Healthy Volunteers |
2024-07-14 |
|
| SME-034-23 | P1 |
Not yet recruiting |
Healthy Volunteers |
2024-05-29 |
|
| AS/CJ/ABR-22/0014 | P1 |
Completed |
Type 2 Diabetes |
2023-02-13 |